PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies

PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving
COPD Therapies

MIDLOTHIAN, Va., June 30 /PRNewswire/ -- In two recent COPD studies sponsored
by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra
II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP,
Mylan Inc.) improves pulmonary function.

"We are pleased that researchers chose PARI products as the exclusive
nebulizer systems for recent studies comparing maintenance treatments for
COPD. Sutherland et al. used an open-label crossover design allowing
researchers to catalog patient preferences regarding medication delivery.
Patients felt greater treatment satisfaction and perceived better control of
their COPD with nebulized formoterol fumarate delivered by PARI's LC Plus and
PRONEB Ultra II. These results are consistent with other studies," said Lisa
Cambridge, RRT, director of clinical development at PARI Respiratory
Equipment.

The Sutherland et al. study, published in Current Medical Research and
Opinion, compared nebulized formoterol fumarate to ipratropium/albuterol
delivered via a metered dose inhaler. The study concluded that nebulized
formoterol fumarate significantly improved pulmonary function and was more
satisfactory to COPD patients than treatment with ipratropium/albuterol
delivered via MDI.

The Tashkin et al. study, presented at the American Thoracic Society
conference last month, looked at the effectiveness of adding nebulized
formoterol fumarate, delivered via PARI's LC Plus and PRONEB Ultra, to
maintenance tiotropium compared to placebo/tiotropium. The study concluded
that adding nebulized formoterol fumarate to maintenance tiotropium in COPD
subjects provided significant improvements in pulmonary function, dyspnea, and
rescue albuterol use over tiotropium alone. The incidence of adverse events
was lower during treatment with formoterol/tiotropium compared to
placebo/tiotropium.

The PARI LC Plus nebulizer and PARI PRONEB Ultra compressor were used
exclusively in pivotal clinical trials for Perforomist Inhalation Solution and
are listed in the package insert.

About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast and efficient
aerosol delivery systems for patients with asthma, chronic lung disease, and
cystic fibrosis. PARI's worldwide vision is to improve the lives of those
affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC
PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the
award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol
mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved
holding chamber improves the aerosol deposition of metered dose inhalers
(MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide
headquarters in Starnberg, Germany. Online at www.Pari.com

Additional information is available by contacting Kirsten Ayars at
805-845-5682 or Ashley Weigand at 804-253-7274 x711.

SOURCE PARI Respiratory Equipment, Inc.

Kirsten Ayars, +1-805-845-5682, or Ashley Weigand, +1-804-253-7274, ext. 711,
both of PARI Respiratory Equipment, Inc.